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Abstract  
Orotic acid, a heterocyclic compound also known as vitamin B13, has shown potent antimalarial 
and cardiac protection activities, however, its limited water solubility has posed a barrier to its 
use in therapeutic approaches. Aiming to overcome this drawback, three orotic acid freeze-dried 
nanocrystal formulations (FA, FB and FC) were developed by using the high-energy milling 
method. Polysorbate 80 (FA) and povacoat® (FC) were used alone and combined (FB) as 
stabilizers. Nanocrystals were fully characterized by dynamic light scattering (DLS), laser 
diffraction (LD), transmission electron microscopy, thermal analysis (TG/DTG and DSC) and X-
ray powder diffraction (XRD) revealing an acceptable polydispersity index, changes in the 
crystalline state with hydrate formation and z-average of 100-200nm, a remarkable 200-time 
reduction compare to the orotic acid raw material (44.3µm). Furthermore, saturation solubility 
study showed an improvement of 13 times higher than the micronized powder. In addition, 
cytotoxicity assay revealed mild toxicity for the FB and FC formulations prepared with 
povacoat®. Orotic acid nanocrystal platform can deliver innovative products allowing untapped 
this versatile potential of this drug substance candidate. 
Keywords   
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Introduction 
Orotic acid is a heterocyclic compound, whose structure, functions and potential 
pharmacologic actions have been studied for many years. This compound, also named vitamin 
B13, is produced by the human intestinal flora and it is found in many biological processes. It 
actively participates in the urea cycle and it is one of the precursors in pathway synthesis de 
novo of pyrimidines for replication of DNA and RNA. 1,2  
One of the most relevant pharmacological findings is its antimalarial action. Orotic acid 
derivatives can inhibit the activity of two key enzymes in Plasmodium replication within the host: 
dihydroorotase and dihydroorotate dehydrogenase 3 showing a desirable selective toxicity. The 
parasite dies from pyrimidine deficiency, while the patient is able to maintain their pyrimidine 
synthesis of uridine and cytidine nucleotides.4 
Furthermore, studies in animals have shown that orotic acid can provide cardiac 
protection, contributing to the prevention of myocardium degeneracy and heart failure in animals 
with genetic cardiomyopathies.5 Additionally, some researchers revealed the use of orotic acid 
as a food supplement for high-performance athletes. Its effects occur during physical activities 
by improving and maintaining ATP levels in glucose uptake. This increases the formation of 
ribose and muscle carnosine storage, supporting and strengthening muscle hypertrophy and 
increasing the contractile capacity of muscle.6,7,8 In the cosmetic area, it presents a moisturizing 
effect on skin, with an effect comparable to excipients with highly moisturizing properties, such 
as the pyrrolidone carboxylic acid (PCA). 
Although orotic acid presents potential therapeutic properties, its aromatic nature, 
characterized by the presence of a pyrimidine ring confers low-water solubility to the molecule in 
the physiological pH range.9 Aiming to overcome this limitation, the development of orotic acid 
synthetic derivatives with improved solubility has been explored as an alternative approach. 
These modifications take advantage of its multidentate structure by adding substituents in its 
pyrimidine ring, in the heterocyclic nitrogen atoms in the carboxylic oxygens, as well as in the 
carboxylic group.10 However, the efficacy of these compounds remains unknown. 
Recent advances in drug delivery systems can overcome this solubility problem, while 
maintaining the drug safety profile, such as the use of nanotechnologies. Among these, 
nanocrystal drugs are one of the most effective approaches. 11,12 Nanocrystals are defined as 
nanometer-sized particles produced from pure drugs, which are usually stabilized by surfactants 
and/or polymeric steric stabilizers present in the dispersion medium. In addition, they are 
obtained in a liquid dispersion, called nanosuspension.13, 14,15 They have been present in the 
pharmaceutical market since the 2000s, when Rapamune® (immunosuppressant) was 
launched. Ever since, they have been one of the most promising nanostructures, due to their 
high earnings and low time-to-market character. By 2017 the FDA has received more than 80 
applications for nanocrystal drug products.16 Nowadays nanocrystals comprise a list of at least 
17 products on market such as  Emend® (prevention of chemotherapy-induced nausea and 
vomiting), Tricor® (cholesterol-lowering drug), Triglide® (lipid regulation), Avinza® 
(phychostimulant), Ritalin LA® (central nervous system stimulant), Zanaflex® (muscle relaxant), 
Megace® (improvement of appetite and increase in body weight in patients with cancer-
associated anorexia) and Naprelan® (anti-inflammatory). 11,13,17,18 To the best of our knowledge, 
there is no orotic acid nanocrystal reported in the literature. 19, 15 
             Different technologies were developed to obtain nanocrystals. In general, the processes 
are classified into two categories, top-down and bottom-up. 20,21 Among these technologies, 
high energy milling, a top-down method, is impressive due to several advantages, such as the 
short time required in the process and the simplicity in development and in the scaled-up 
production. 22,23,24 Despite these numerous advantages, the additional free energy of the new 
surfaces generated by the milling need to be compensated to avoid instability, which can be 
achieved by the use of proper stabilizers. 19,20,21 As the selection of stabilizers is often                   
drug-specific, the search for new and more efficient stabilization systems is needed. 25,26   
Recently, Povacoat®, a polyvinyl alcohol co-polymer derivative, has been pointed out as a 
promising new stabilizer for nanocrystal formulations. 27,28 In the present study, we report the 
beneficial effects of the use of this co-polymer and a new combination with polysorbate 80, one 
of the most popular stabilizers, for the development and cytotoxicity evaluation of orotic acid 
nanocrystals.  
 
Experimental section 
Materials 
         Orotic acid (OA) anhydrous (purity 99.8%) (Figure 1) was purchased from Sigma Aldrich 
(São Paulo, Brazil). Methylcellulose, polysorbate 80, methylparaben and glucose were obtained 
from Shin-Etsu (Tokyo, Japan). Povacoat® Type F (Polyvinyl alcohol/ Acrylic acid/ Methyl 
methacrylate copolymer) was donated from Daido Chemical Corporation (Osaka, Japan). 
Hydrochloric acid, sodium chloride, sodium citrate, sodium acetate, potassium phosphate 
monobasic, and sodium hydroxide were obtained from Synth (Sao Paulo, Brazil). Purified water 
was obtained from a Milli-Q Millipore water system (São Paulo, Brazil). The cell line NCTC clone 
929 was donated from the Culture Section of the Cell Institute Adolfo Lutz (São Paulo, Brazil). 
The culture media was purchased from Interlab (São Paulo, Brazil). 
 Figure 1. Molecular structure of orotic acid. 
 
Methods 
Preparation of orotic acid nanocrystals 
         Orotic acid nanocrystals were prepared using a rotation revolution nanopulverizer NP-100 
(Tokyo, Japan) according to the method proposed by Takatsuka et al. 22. Prior to the 
nanopulverization, a dispersion medium was prepared by dissolving the following stabilizers: 
methylcellulose (0.3% w/v), povacoat® (10% w/v) and polysorbate 80 (0.1% w/v) in the water. 
Three formulations were prepared using polysorbate 80 (FA), polysorbate 80 and povacoat® 
together (FB) and povacoat® (FC). The concentration of the orotic acid was maintained 
constant at 10% (w/v).  
The nanopulverization was performed in two steps.  In the first step, 10 g of orotic acid 
and 50g of the aqueous solution containing the stabilizers were transferred to the mixing vessel. 
A total of 35g of yttrium-stabilized zirconia milling beads with a diameter of 0.1 mm were added 
to the same container. At this stage, the conditions for pulverization were 1,500 rpm for 15 
minutes. For the second step, 50g of aqueous solution containing the stabilizers were added to 
the vessel and the conditions applied were 400 rpm for 1 minute. 
From the nanosuspensions obtained, an amount of 10 g was immediately freeze dried 
(Christ Alpha 1-5, Christ Martin, Germany) at -70°C for 48 hours under pressure of 0.120 mbar 
and 24 ° C using glucose (up to 5g) to prevent aggregation. 
 
Characterization of orotic acid nanocrystals 
Process efficacy and influence of the stabilizer on particle size and zeta potential and 
stability  
Orotic acid particle size distribution was measured using laser diffraction (LD) technique 
(Mastersizer 2000, Malvern Instruments, England) with a small volume dispersing unit (Hydro 
2000uP, Malvern Instruments, England). Samples were diluted 20-fold using Ultrapure Milli-Q® 
water. The nanocrystals z-average was measured by dynamic light scattering (DLS) technique 
using a Zetasizer Nano ZS device (Malvern Instruments, England). The samples were diluted in 
Milli-Q® in the ratio of 1:400 (nanocrystal:water). Measurements were performed in triplicate 
using a measurement angle of 90°. 
The zeta potential was determined employing a Zetasizer Nano ZS 90 device (Malvern 
Instruments, Malvern, UK). Samples (n=3) were prepared using 20μl of a diluted 
nanosuspension in 4 mL of Milli-Q® water. The conductivity of the dispersion was adjusted to 
50 µS/cm, with NaCl solution at pH 5.5. 29 
The stability of the freeze-dried nanosuspensions, kept under refrigeration (4°C), was 
evaluated by monitoring the variations in particle size distribution and z-average, polydispersity 
index and zeta potential values, for 3 months. Data were analyzed using Minitab 17 Statistical 
Software® by analysis of variance (ANOVA) and regression analysis. P-values less than 0.05 
were considered statistically significant. Additionally, macroscopic observations aiming to detect 
sediment and agglomerates in the redispersed nanosuspensions were performed monthly. 
 Scanning Electron Microscopy 
Orotic acid raw material was analyzed using a SU-1500 scanning electron microscope 
(SEM) (Hitachi High-Technologies, Tokyo, Japan). Samples were measured using 15kV 
acceleration voltage and images were acquired using 500x magnification. The morphology and 
particle size of nanocrystals were observed using a transmission electronic microscopy JEM-
1010 with 80 kV (Jeol USA). Samples were obtained from a saturated solution and diluted 10x. 
The material was deposited on copper grids and coated with 150 MESH Formvar film for 10 
minutes. In addition, Image J® Software was used for the crystal size confirmation. The analysis 
was performed individually for orotic acid raw material, FA, FB and FC, for which 30 crystals 
were measured per sample (n = 30). 
 
Thermal analysis 
Differential scanning calorimetry (DSC) curves were obtained in a DSC 7020 (Exstar, 
Japan). About 2 mg of samples (pure materials, physical mixture, and nanocrystals) were 
placed in an aluminum sample holder hermetically sealed and subjected to analysis. Dynamic 
N2 atmosphere (50 mL min-1) and a heating rate of 5°C min-1 in the temperature range of 25 to 
300°C were used. The temperature range and enthalpy response were previously calibrated 
using an indium standard. 
Thermogravimetry and derivative thermogravimetry (TG/DTG) curves were obtained 
using a TG / DTA 7200 (Exstar, Japan), with sample weight of approximately 5mg (platinum 
crucible) at a heating rate of 5°C min -1, under dynamic N2 atmosphere (100 mL min-1) in the 
temperature range 25 to 600°C. The instrument calibration was verified employing calcium 
oxalate standard. 
 
X-ray diffraction 
A Bruker Diffractometer Model D8 Advance Da Vinci (Bruker, Japan) was used to 
characterize the solid crystalline state. Samples of the physical mixture in absolute values and 
nanocrystals were exposed to Cu Ka radiation 40 Kv. Measurements were performed at a 
scanning speed of 0.5°/min over a 2θ range of 0.01–40°. 
 
Determination of saturation solubility 
The saturation solubility of FA, FB and FC was determined by Shake-Flask method. 30 
The media were determined in an exploratory experiment where orotic acid showed more 
solubility in media acetate pH 4.5 and water. The formulations were added to vials containing 10 
mL media. After reaching saturation, the vials were properly sealed and transferred to a shaker, 
430-RDBPE model (New Ethics, São Paulo, Brazil) at 37° C for 72 hours. At the end of that 
period, aliquots were collected; filtered using a porous micron Full-Flow 45μm filter (Millex GM, 
Millipore, Massachusetts, USA) and the solubilized amount of orotic acid was determined by 
spectrophotometric method. 
 
Determination of orotic acid content 
Orotic acid content in the nanosuspension was determined by UV spectrophotometry 
using an Evolution™ 201 UV-Visible Spectrophotometers (Thermo Scientific, São Paulo, Brazil) 
and wavelength of 274nm. The method was developed and validated in the parameters of 
specificity, linearity, accuracy and precision. 
 
Cytotoxicity 
Cell line NCTC clone 929 (mouse connective tissue) CCIAL020, grown in minimal 
medium Eagle (MEM) supplemented with 0.1 mM non-essential amino acids, 1.0 mM sodium 
pyruvate and 10% fetal bovine serum without antibiotic was used in the agar diffusion method. 
31,32 Samples were tested in four replicates on separate plates; for the positive controls, latex 
fragments (toxic) were used (0.5cm x 0.5cm); and negative controls were filter paper discs, 
respecting the dimensions of 0.5 cm in diameter. Samples were analyzed macroscopically 
observing the presence or absence of a clear halo in or around the test sample. The diameters 
of these halos, when present, were accurately measured, using a calibrated pachymeter. The 
average of the readings of halo diameters of four plates was calculated.  
 
Results and Discussion 
Process efficacy and influence of the stabilizer on particle size and zeta potential and 
stability  
The z-average, the polydispersity index (PDI) and zeta potential (ZP) of FA, FB and FC 
were obtained immediately after preparation. The mean particle size values of nanocrystals 
were 116± 5nm (FA), 115± 6nm (FB) and 120± 6nm (FC). PDI was 0.170; 0.162; 0.188 and the 
ZP was-28.2±5.7mV, -3.2±7.2mV and -2.2±6.1mV, respectively for FA, FB and FC. The weight 
mean volume D[4.3] of the OA raw material determined by LD was 26.1µm. The surface 
weighted mean D[3.2] was 18.5 µm and the PDI value was 0.424.  Additionally, the diameter at 
10, 50 and 90% of the cumulative population distribution were d0.1=11.7 µm, d0.5=23.9 µm and 
d0.9=44.3 µm. Comparing with FA, FB and FC, the reduction in particle size was more than 200 
times in all formulations (raw material d0.5=23.9 µm; (FA)116± 5nm, (FB)115± 6nm and 
(FC)120±6nm. These results indicate a highly effective performance of the high energy milling 
method of producing orotic acid nanocrystals. As examples for comparisons, Takatsuka et al. 22  
prepared nanocrystals of 5 poorly water-soluble compounds (BCS class II and IV) by high-
energy milling. The most notable reduction was obtained for nifedipine with the particle size 
reduction of d0.5 in 105 times (d0.5=14.6mm to 139nm). Similarly, Barbosa et al. 17 obtained 
furosemide nanocrystals by the same method reducing the d0.5 about 29 times from particles of 
3.6µm down to d0.5 of 122nm. 
The stability study was performed using the dry formulation storage in glass vessel at 
4°C. The z-average, PDI and ZP values obtained during the 3 months in the stability test are 
presented in Figure 1. After 3 months, the values obtained were 182±5nm, 116±5nm and 
117±4nm, demonstrating that only the formulation without povacoat® (FA) presented an 
increase in z-average over the period of three months. Povacoat® (Figure 2) is a new aqueous 
PVA copolymer which has demonstrated potential to effectively prevent the aggregation of 
nanoparticles of poorly water-soluble compounds. The main advantages of using polymers 
instead of conventional stabilizers as Polysorbates comprises the potential to minimize the 
molecular motion of the dispersed drug in the solution, prevent the crystal growth and 
nucleation of the dissolved drug, maintaining the supersaturation level for a long period of time 
and improve the storage stability by inhibiting the recrystallization of amorphous drug. In 
addition, Povacoat® exhibit both hydrophobic and hydrophilic properties, so the surface of a 
poorly water-soluble compound can be properly wetted and then sterically stabilized in a liquid 
medium.  27,28 The low ZP values observed in the Povacoat® formulations (FB and FC) indicate 
a sterically-stabilized system, what possibly compensate the free energy of the new surfaces 
created and help to avoid agglomeration, nucleation and crystal growth, however, the main 
stabilization mechanisms are still unclear and further investigation is needed to develop better 
and more rational screening strategies. Additionally, the PDI of FA was increased to 0.452, 
while for FB and FC there were no significant changes in the PDI values. Values higher than 
0.500 are related to the Ostwald ripening, being considered critical in the formulation. 33, 34 
 
Figure 2.  The chemical structure of water-soluble polymer povacoat® type F. 
ZP analysis is based on the assessment of the movement of the particles in an electric 
field, being a fundamental parameter in the prediction of long-term stability. At the end of the 
third month, ZP values were -30.3±8.4mV, -4.7±7.5mV and -9.8±7.2mV, respectively for FA, FB 
and FC. A  zeta potential of at least -30mV, for electrostatic and -20 mV for sterically stabilized 
systems is desired to obtain a physically stable nanosuspension.35 However, there is no general 
rule. 36,37,38,39 ZP values are dependent on the type, size, molecular weight and other stabilizer 
characteristics.  Müller et al 39 established the ZP value of polysorbate alone (-13 mV) and 
posteriorly this value in a very sterically-stabilized system (-3 mV). The authors observed that 
ZP values lower than -30 mV and -20 mV can be observed without breakage in the system. By 
contrast, the use of polysorbate was reported as critical for long-term stability due to its 
relatively thin adsorbed layer in the nanoparticles.38,40 In summary, the feasibility of its use 
should be monitored case-by-case. In the present study aiming to provide effective steric 
stabilization, different classes of stabilizers were used: a non-ionic surfactant (polysorbate 80), a 
semisynthetic non-ionic polymer (methylcellulose), and a polymer (povacoat®). Their influence 
on the stability was statistically evaluated. 
Additionally, both formulations were easily resdispersed with water during this period. In 
contrast, FA was challenging to redisperse in water, after liophylization, possibly due to the 
irreversible nanocrystal aggregation. 
The results from the stability study were evaluated using ANOVA, a parametric method, 
which is a reliable and powerful in detecting differences in quantitative data.  In ANOVA 
analysis, values of a significance level (p-values) less than 0.05 (α = 0.05) indicate statistically 
significant models. 41 Thus, ANOVA was used as a statistical tool to evaluate the interaction 
among storage time, povacoat® and polysorbate 80, on z-average, ZP and PDI. For z-average 
(Figure 3a), povacoat® and storage time presented p-values <0.05, 0.008 and 0.02, 
respectively. For ZP (Figure 3b), povacoat®, polysorbate 80 and time presented p-values of 
0.001, 0,440 and 0.066. For PDI (Figure 3c), p-values were 0.012 for povacoat® and time.  In 
summary, these analyses showed that povacoat® and the storage time influenced the stability of 
the nanocrystals. The analysis also revealed that the total absence of this polymer was the 
determining factor for increasing the z-average and PDI values. A similar advantage of this 
polymer was identified by Yuminoki et al. 42 to stabilize Griseofulvin, Probucol, Tolbutamide and 
Hydrochlorothiazide nanocrystals by using high-energy milling. The author found povacoat® was 
the most effective in preventing nanocrystal aggregation compared to hydroxypropylcellulose 
(HPC), and polyvinylpyrrolidone (PVP).  
 
 Figure 3.  (a) Z-average, (b) zeta potential and (c) polydispersity index of FA, FB and FC for 
three months. 
 
 
SEM analysis 
One of the main advantages of using microscopy techniques in characterizing 
nanocrystal is to reveal its size independent of the particle shape.  Keck 43 pointed out a critical 
shortcoming of these traditional measurement techniques. According to the author, DLS and DL 
techniques assume sphere-shaped particles for the measurement of the z-average and particle 
size distribution, respectively. In general, nanocrystals rarely present a sphere shape. Thus, the 
particle size obtained is estimated, demonstrating the importance of using a supplementary 
technique to overcome this limitation.44  
Microscopy images (Figure 4) revealed differences in size, surface, and shape of OA 
raw material (Figure 4a) compared to nanocrystals (Figure 4b, 4c and 4d). Additionally, they 
revealed the presence of clusters of OA raw material (Figure 4a), which confirms the results 
obtained previously by DLS and DL (PDI 0.424). For FA, although PDI was 0.179±0.05 using 
the DLS technique, microscopy images showed aggregation (Figure 4b). Moreover, it is 
possible to observe the effectiveness of the milling process in the reduction of the particle size 
(Figure 4b, 4c and 4d). The Image J software allowed determining the crystal particle size, 
being 354±45nm, 141±22nm and 116±26nm respectively for FA, FB and FC (n=30). Due to the 
diversity in shape and size that nanocrystals can present, software such as Image J are being 
widely used to certify these parameters, even when the traditional methods (DLS and DL) are 
used. 45- 49 
Orotic acid nanocrystals apparently presented a needle-shape for all formulations. 
Nanocrystal shape is a distinct parameter of each substance and is closely related to the type of 
vessel, centrifugal force, running time and specific characteristics of the zirconia balls used 
during the milling process. 22  
 
Figure 4. Images of OA raw material (a), FA (b), FB (c) and FC (d). 
 
Thermal analysis 
Thermal properties of OA raw material and FA, FB and FC were evaluated by DSC 
(Figures 5a, 5d and 5g respectively), TG (Figures 5b, 5e and 5h) and DTG (Figures 5c, 5f and 
5i) analysis. TG profile of OA indicates the presence of two main events during the mass loss. 
The first event occurs between 100 and 150 °C and corresponds to the sample dehydration, 
suggesting that the anhydrous OA probably was converted into a hydrate during transport or 
storage. According to Braun et al. 50, anhydrous OA can transform into the hydrate form during 
storage time, depending on relative humidity of the environment. Also, a second step assigned 
to sublimation occurs at 330 °C, corresponding to a mass loss of 99.8%, which is followed by a 
slow final decomposition step.   
TG/DTG curve of FA (Figures 5b and 5c) exhibits the first mass loss between 50 °C and 
80 °C (Δm = 2.6%; Tpeak = 70 °C), which is assigned to dehydration. Posteriorly, five additional 
events with consecutive mass loss (Δm1 = 5.4%, Δm2 = 9.7%, Δm3 = 17.2% and Δm4 = 53.8%) 
in the range from 105 °C to 335 °C (DTGpeak = 105 °C, 169 °C, 256 °C and 335 °C), followed by 
a slow final step at 355 ºC.  For FB (Figures 5e and 5f) and FC (Figures 5h and 5i), the water 
loss process is less pronounced and it occurs near 50 °C.  Posteriorly, two additional events of 
mass loss are observed at 268 °C (extrapolated onset temperature = Tonset) and 231 °C for FB 
and FC, respectively.  Finally, both formulations present a slow final step between 474 ºC and 
482 ºC.  
           DSC curves confirmed most of the events observed by thermogravimetric analysis. DSC 
curve of FA (Figure 5a) shows a well-defined endothermic event near to 85 °C (Tpeak = 84 ºC), 
confirming the presence of the OA hydrate. For FB and FC, Figures 5d and 5g, respectively, a 
broad endothermic event occurs gradually from 25 °C, indicating the presence of a small 
amount of water superficially adsorbed, i.e. not bound to the structure. These results clearly 
indicate structural differences and that the freeze-drying process was not efficient to remove 
bound water from FA formulation. A second endothermic event in the DSC FA curve 
corresponds to the anticipation of the melting point of glucose (Tpeak = 143 ºC). The third 
endothermic event is observed at about 183 °C (Tpeak = 183 ºC), which suggests the anticipation 
of glucose decomposition. In case of FB/FC, events related to povacoat® melting were 
characterized by endothermic events, occurring from 160 °C to 170 °C, and by exothermic 
recrystallization events at 170 °C and 190 °C. 51 Thereafter, an endothermic event related to the 
decomposition of glucose is observed near 200 °C (Tpeak = 197 ºC), followed by povacoat® 
decomposition between 231°C to 237 °C (FB Tpeak = 231 ºC, FC Tpeak = 237 ºC).  
 
 
Figure 5.  Thermoanalytic profiles obtained in dynamic nitrogen atmosphere (50mL min-1) and 
heating rate 5 °C min-1: (a) DSC, (b)TG and (c) DTG curves of OA raw material, physical 
mixture, excipients and FA. (d) DSC, (e) TG and (f) DTG curves of OA raw material, physical 
mixture, excipients and FB. (g) DSC, (h)TG and (i) DTG curves of OA curves raw material, 
physical mixture, excipients and FC. 
 X-ray diffraction 
The X-ray diffraction pattern of OA raw material exhibited reflections of high intensity, 
narrow and a well-defined boundary, indicating its crystalline nature (Figure 6). The most 
intense peak of OA (at 29 °) is also preserved in the formulations and physical mixture. 
Comparing the OA raw material with FA, FB and FC, we observed that the nanocrystals showed 
lower intensity in the diffraction patterns. This fact is probably caused by the significant 
reduction in the particle size induced by the milling process and the addition of certain degree of 
disorder due to amorphization and/or hydration. 50 FB and FC patterns have more similarities 
between them than compared to FA, in agreement with the thermal analysis results.  
  
Figure 6. X-ray diffractogram of OA raw material, physical mixture, excipients and FA, FB and 
FC. 
 
 
Determination of saturation solubility 
Solubility test was performed using the media acetate pH 4.5 and water, which were 
selected from an exploratory solubility test on OA raw material. In these media OA presented 
higher saturation solubility than pH 1.2 and 6.8 and 7.2. As shown in Table 1, FA, using water, 
revealed the highest increase in the saturation solubility, reaching up to 13 times higher than 
OA raw material. FB exhibited an increase in saturation solubility up to 7.5 times higher in 
acetate buffer pH 4.5 compared to OA raw material. For FC, it was demonstrated that the 
increase in solubility was practically the same in both media: 5 times higher. Barbosa et al 17 
obtained furosemide nanocrystals, using high-energy milling, with saturation solubility between 
1.2 and 3.0 times higher compared to the furosemide raw material.  
According to the study of the physical mixtures no enhancement in saturation solubility 
was observed compared to values of OA raw material (Table 1). These results confirm that the 
improvement in saturation solubility of nanocrystals was due to reduction of the particle size 
revealing innovative physical and chemical characteristics. 52 Among these nanocrystal 
particularities, the most known are the increased surface area, the rise in adhesiveness and 
dissolution rate of poorly water-soluble drugs. These effects are elucidated by Noyes-Whitney, 
Kelvin and Ostwald-Freundlich equations. 53, 54, 44, 21 In general, these properties lead to 
improved bioavailability, provide rapid onset of action, reduction in fasted/fed state variations, 14 
reduction of volume and dosages administered 55, 56 and enhanced skin delivery. 57, 58 
Additionally, some studies demonstrated that high-energy milling was the most effective 
method for preparing oral suspensions for pharmacological, pharmacokinetic, and safety 
studies on animals during the drug discovery and preclinical phase. Furthermore, it has enough 
potential to warrant expanding research into a new approach for preparing extemporaneous 
formulations for the ﬁrst-in-human and early clinical studies of a candidate drug. 22 
 
Table 1. Saturation solubility (n=3) of OA raw material, physical mixtures of FA (PM-
FA), FB (PM-FB) and FC (PM-FC), nanocrystals formulations (FA, FB and FC) and 
the increase in solubility. 
Formulation 
 
Media (mg/mL) 
Increase in 
solubility (times) 
       Water 
       Acetate  
       pH 4.5 Water 
Acetate 
pH 4.5 
OA 0.10 0.11 0.10 0.20 0.18 0.19 RV RV 
PM- FA 0.09 0.10 0.09 0.21 0.20 0.20 - - 
PM- FB 0.11 0.11 0.10 0.22 0.21 0.21 - - 
PM- FC 0.11 0.10 0.10 0.19 0.20 0.20 - - 
FA 1.35 1.37 1.36 2.20 2.22 2.20 13.6 11.0 
FB 0.65 0.66 0.63 1.50 1.48 1.51 6.3 7.5 
FC 0.65 0.56 0.56 1.02 1.03 1.04 5.6 5.0 
RV: reference value; - : not observed; OA: orotic acid raw material; PM-FA: physical 
mixtures of orotic acid, methylcellulose, polysorbate 80 and glucose; PM-FB: physical 
mixture of orotic acid, methylcellulose, polysorbate 80, povacoat® and glucose; PM-FC: 
physical mixtures of orotic acid, methylcellulose, povacoat® and glucose; FA: 
nanocrystal formulation FA; FB: nanocrystal formulation FB; FC: nanocrystal formulation 
FC. 
 
 
Cytotoxicity 
The agar diffusion test is a qualitative assessment of toxicity, which is used as a 
screening evaluation in developing process of new products due to its practicality and low cost. 
This method proved to be suitable for screening assays and evaluating the toxicity of new 
products basing themselves on their ability to predict irritation in vivo. In addition, it contributes 
significantly to reducing animal assays. 59-62 According to US Pharmacopeia, 32 the cytotoxicity 
of FA, FB and FC were classified by the size of cell death area on the plate. The results can be 
observed in Figure 7. FA (Figure 7c) presented cell death in the entire plate and its graded 
reactivity was Grade 4 (severe toxicity). However, both FB (Figure 7d) and FC (Figure 7e), 
showed average cell death area of 0.1333 cm and 0.139 cm, respectively, and were graded as 
Grade 2 (mild toxicity). The severe cytotoxicity shown by FA could be explained due to the high 
concentration of OA in formulation (42.5%). FB and FC showed mild toxicity probably due to the 
difference of excipients in the formulations; besides the OA content was more than 3 times 
lower than in FA. While the nanocrystals might be used as a primary formulation, this toxicity 
presented by the FA must be investigated, considering the concentration that will be used in the 
final product.  
 Figure 7. Images of cytotoxicity assay. Negative control (a), Positive control (b) FA (c), FB (d) 
and FC (e). 
 
 
Conclusion 
High-energy milling technique successfully allowed a particle size reduction of orotic 
acid to the nanosize range (100- 200 nm). The nanocrystals obtained presented a significant 
increase in the saturation solubility compared to orotic acid raw material, up to 13 times. 
Povacoat®, as stabilizer agent, provided stable formulations with improved and better 
physicochemical characteristics.   Additionally, cytotoxicity assay revealed mild toxicity for the 
stable formulations which could be improved by controlling the final concentration in the 
formulation. Thus, orotic acid nanocrystals produced with povacoat® have the potential, as a 
platform, to develop unique drug products, cosmetics and food supplements. 
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